13 October 2022 | News
$97 million investment enhances bioanalytical services, helping pharma and biotech customers accelerate drug development
image credit- Thermo Fisher
Thermo Fisher Scientific has expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, Virginia in the US. The new unit will support increasing demand across biopharma for consistent, high-quality laboratory services to accelerate drug development.
The 59,000-square-foot facility is part of the previously announced $97 million investment by the company to expand its bioanalytical laboratory operations in Richmond and add more than 500 jobs over the next three years.
The current laboratory services operation in Richmond, which Thermo Fisher acquired through the purchase of PPD, Inc. in December 2021, now comprises more than 350,000 square feet, making it one of the largest laboratories of its kind in the world. The entire Richmond operation employs about 1,300 local professionals, including Ph.D.-level scientists, analytical laboratory staff and other scientific professionals. The bulk of the expansion with this new facility will occur in liquid chromatography-mass spectrometry for drug discovery through to clinical testing, as well as subsequent enhancements in cell and gene therapy, biomarkers, vaccine sciences and immunochemistry.
In addition to bioanalytical, biomarker and vaccine sciences labs in Richmond, Thermo Fisher’s clinical research business includes bioanalytical and good manufacturing practices (GMP) labs in Middleton, Wisconsin; a GMP lab in Athlone, Ireland; central labs and biomarker operations in Brussels, Belgium, Highland Heights, Kentucky, and Singapore; and bioanalytical, biomarker, vaccine sciences and central labs in Suzhou, China.